Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
With a market cap of 125.79B, Vertex Pharmaceuticals(VRTX) trades at $494.56. The stock has a price-to-earnings ratio of 32.08.
As of 2026-02-16, Vertex Pharmaceuticals(VRTX) stock has fluctuated between $465.00 and $503.88. The current price stands at $494.56, placing the stock +6.4% above today's low and -1.8% off the high.
The Vertex Pharmaceuticals(VRTX)'s current trading volume is 2.92M, compared to an average daily volume of 1.7M.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $519.68 at its peak.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $519.68 at its peak.
VRTX News
Vertex Pharmaceuticals (NasdaqGS:VRTX) has entered into an agreement with WuXi Biologics to develop a trispecific T-cell engager for B-cell mediated autoimmune...
If you are wondering whether Vertex Pharmaceuticals at around US$491.47 is still a sensible entry or hold, the starting point is understanding what you are actu...
Vertex Pharmaceuticals Inc. ((VRTX)) has held its Q4 earnings call. Read on for the main highlights of the call. Valentine's Day Sale - 70% Off Unlock hedge fun...
Analyst ratings
76%
of 33 ratingsMore VRTX News
Vertex Pharmaceuticals (VRTX) is back in focus after reporting full year 2025 results and issuing 2026 revenue guidance tied to its cystic fibrosis franchise an...
Key Points CRISPR Therapeutics’ fourth quarter was relatively disappointing. As a biotech start-up still in its infancy though, these early quarterly numbers...
Investors eyeing a purchase of Vertex Pharmaceuticals, Inc. (Symbol: VRTX) stock, but cautious about paying the going market price of $494.38/share, might benef...
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $570 from $564 and keeps an Overweight rating on the sha...
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) shares are trending on Thursday night. Shares of the Massachusetts-based biotechnology company fell 1.24% in after-ho...
Image source: The Motley Fool. Thursday, Feb. 12, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Reshma Kewalramani Chief Commercial Officer...
Reports Q4 revenue $3.19B, consensus $3.17B. “2025 marked a year of strong revenue growth, commercial diversification, and pipeline advancement,” said Reshma Ke...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.